Table 2.
Association between gene sets and ovarian cancer survival in cases with high-grade serous (HGS) histological subtype (p < 0.005).
| Source | Gene Set | No. SNPs | No. Genes | GS P-value |
|---|---|---|---|---|
| GO:BIO | intracellular signaling pathway | 22,715 | 857 | 7.3 ×10−5 |
| GO:BIO | regulation of cell-substrate junction assembly | 195 | 8 | 4.0 ×10−4 |
| GO:BIO | anatomical structure formation involved in morphogenesis | 9,701 | 375 | 5.3 ×10−4 |
| GO:CELL | organelle outer membrane | 2,023 | 109 | 5.8 ×10−4 |
| GO:BIO | negative regulation of focal adhesion assembly | 114 | 5 | 5.8 ×10−4 |
| GO:MOLE | macrolide binding | 126 | 8 | 6.2 ×10−4 |
| GO:MOLE | cis-trans isomerase activity | 318 | 34 | 7.5 ×10−4 |
| GO:BIO | negative regulation of odontogenesis | 41 | 2 | 8.2 ×10−4 |
| GO:BIO | osteoblast differentiation | 1,976 | 70 | 8.4 ×10−4 |
| GO:BIO | axis specification | 420 | 29 | 1.0 ×10−3 |
| GO:CELL | photoreceptor inner segment | 211 | 9 | 1.1 ×10−3 |
| GO:CELL | outer membrane | 2,131 | 113 | 1.1 ×10−3 |
| GO:BIO | negative regulation of molecular function | 5,927 | 331 | 1.6 ×10−3 |
| GO:BIO | regulation of response to cytokine stimulus | 24 | 3 | 1.7 ×10−3 |
| GO:MOLE | SH3/SH2 adaptor activity | 1,283 | 51 | 1.7 ×10−3 |
| GO:BIO | homeostatic process | 17,434 | 769 | 1.8 ×10−3 |
| GO:BIO | embryo implantation | 507 | 26 | 1.9 ×10−3 |
| GO:BIO | tissue homeostasis | 1,818 | 70 | 1.9 ×10−3 |
| GO:BIO | chromatin disassembly | 30 | 5 | 1.9 ×10−3 |
| GO:BIO | ossification | 3,808 | 161 | 2.0 ×10−3 |
| GO:MOLE | protein dimerization activity | 13,527 | 540 | 2.1 ×10−3 |
| GO:BIO | bone development | 3,913 | 169 | 2.2 ×10−3 |
| GO:BIO | regulation of odontogenesis | 194 | 8 | 2.3 ×10−3 |
| GO:BIO | regulation of cell adhesion | 3,760 | 123 | 2.5 ×10−3 |
| GO:BIO | anatomical structure morphogenesis | 33,110 | 1244 | 2.5 ×10−3 |
| GO:BIO | signal transmission | 78,767 | 3523 | 2.5 ×10−3 |
| GO:BIO | somatic stem cell maintenance | 244 | 12 | 2.7 ×10−3 |
| GO:BIO | multicellular organismal homeostasis | 2,259 | 92 | 2.8 ×10−3 |
| GO:MOLE | protein binding, bridging | 2,037 | 96 | 2.9 ×10−3 |
| GO:BIO | organ morphogenesis | 12,461 | 554 | 2.9 ×10−3 |
| GO:BIO | peptide transport | 2,067 | 87 | 3.0 ×10−3 |
| PharmGKB | Glucocorticoid & Inflammatory genes (PD) | 146 | 9 | 3.1 ×10−3 |
| GO:MOLE | protein transmembrane transporter activity | 97 | 14 | 3.2 ×10−3 |
| GO:BIO | cell migration | 11,535 | 386 | 3.4 ×10−3 |
| GO:BIO | negative regulation of biological process | 38,075 | 1805 | 3.4 ×10−3 |
| GO:BIO | intracellular transport | 12,735 | 700 | 3.5 ×10−3 |
| GO:BIO | multicellular organismal macromolecule metabolic process | 954 | 41 | 3.5 ×10−3 |
| GO:BIO | signal transduction | 66,542 | 3130 | 3.7 ×10−3 |
| GO:BIO | muscle homeostasis | 989 | 13 | 3.8 ×10−3 |
| GO:CELL | beta-catenin destruction complex | 87 | 6 | 4.0 ×10−3 |
| GO:BIO | negative regulation of response to cytokine stimulus | 8 | 1 | 4.7 ×10−3 |
| KEGG | TGF-beta signaling pathway | 1,359 | 86 | 4.7 ×10−3 |
| GO:BIO | stem cell maintenance | 414 | 25 | 4.7 ×10−3 |
Adjusted for age, study site, and population structure.